Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Minister Touts “Balanced” Off-Year Revision after USCC Letter
Health Minister Takamaro Fukuoka on February 18 explained the purpose of the off-year drug price revision in FY2025 in response to a letter of protest sent from the US Chamber of Commerce (USCC) over Japan’s recent pharmaceutical policies, including such…
To read the full story
Related Article
- US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
- MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
March 13, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
- MHLW Not Yet Able to Examine Letters of Protest by US Lobbies: Minister
February 13, 2025
- US Lobbies Send Letters of Protest to Japan Embassy over Off-Year Revision, CEA
February 10, 2025
REGULATORY
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
- Three Sent to Prosecutors over Alleged Illegal Mounjaro Sales
June 3, 2026
- LDP Group Eyes Proposal to Address Challenges in Radiopharmaceutical Use
June 3, 2026
- Japan OKs Dosage Change for Colchicine after Fatal High-Dose Cases
June 3, 2026
- Japan Measles Cases Top 500 This Year: JIHS
June 3, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…